Use in Adolescents

Use in Adolescents

The 50μg/5μg and 125μg/5μg doses of flutiform are indicated for use in patients aged 12 years and over1

The prevalence of asthma symptoms in children in the UK is among the highest in the world,2 and asthma is the most common long-term condition experienced by children and young people.3

In this group of patients, it is important to encourage effective inhaler use and adherence with prescribed medication, as well as development of self-management skills.3

The National Review of Asthma Deaths found that poor recognition of the risks associated with their condition was an important avoidable factor in 83% of 10–19-year-olds being looked after in primary care who died as a result of their asthma. In children and young people, an apparent lack of adherence to medical advice was also common.4

  • In a 2-year retrospective database study of 153 asthma patients aged between 12 and 80 years, patients who switched to flutiform from Seretide Evohaler showed increased adherence to their treatment5*

*Baseline outcome data (following 12 months using Seretide Evohaler) were compared with outcome data (12 months after the switch to flutiform). Secondary endpoint; mean (90.3% vs. 86.7%; P=0.027)5


  1. Napp Pharmaceuticals Limited. flutiform® summary of product characteristics. [Accessed February 2018].
  2. Asthma UK. Asthma facts and statistics. [Accessed February 2018].
  3. Primary Care Commissioning. Designing and commissioning services for children and young people with asthma: A good practice guide. [Accessed February 2018].
  4. Royal College of Physicians. Why asthma still kills. The National Review of Asthma Deaths (NRAD). [Accessed February 2018].
  5. Lim D, Small I, Wolfe S, et al. Effectiveness of fluticasone-propionate/salmeterol versus fluticasone-propionate/formoterol in UK patients with asthma. Pragmatic and Observational Research Journal 105;6:34-5 [abstract22].